BioLife Solutions Inc. (BULLETIN BOARD: BLFS) announced today that it was granted a U.S. patent that covers the methods and compositions for the preservation of cells, tissues or organs in the vitreous state.

BioLife President and CEO John G. Baust, Ph.D., said that the market for preserving cells and tissue is growing rapidly and is diverging into new technology areas, one of which is vitrification or freezing rapidly to avoid the presence of ice crystals.

Baust said, "Our core preservation technologies can be a critical factor in applying this new technology and solidifying our patent position in that area gives us a commercial foothold as that market develops." He continued, "We believe BioLife holds a unique and encompassing intellectual property position in the biological processing and preservation of cells, tissues and organs and that our technology significantly improves the viability of cells and organs for longer periods of time during transportation and storage."

The issuance of the patent specifically provides BioLife with the latest extension of its molecular-based cryopreservation technology platform and protects BioLife's use of cell death inhibitors (calpain inhibitors) in hypothermic preservation solutions necessary to improve cryopreservation outcome. With this patent the scope of the Company's proprietary preservation technology extends into the cell, tissue and organ vitrification arena by including the Company's molecular-based approaches to preservation to prevent apoptotic and necrotic cell death following the preservation process.

This patent, No. 6,921,633, titled, "Methods and compositions for the preservation of cells, tissues or organs in the vitreous state," brings the total number of issued patents that relate to its preservation solutions to four.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol® and CryoStor™ products that the Company is selling today are a significant step forward in meeting these needs.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

   Contact:  Allen & Caron Inc
             Jill Bertotti (investors)
             jill@allencaron.com
             Len Hall (media)
             len@allencaron.com
             949-474-4300

SOURCE: BioLife Solutions Inc.